8-K: Annovis Bio Receives Notice of Non-Compliance from NYSE Due to Low Market Cap and Stockholders' Equity

Annovis Bio, Inc. received a notice from the NYSE regarding non-compliance with continued listing standards due to its market capitalization and stockholders' equity falling below the required thresholds.

Summary

• Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) on March 26, 2025, indicating non-compliance with continued listing standards.
• The non-compliance is due to the company's average market capitalization falling below $50 million over a 30-day trading period, while also having stockholders' equity less than $50 million.
• As of March 25, 2025, Annovis Bio's 30-day average market capitalization was approximately $37.9 million, and its stockholders' equity as of December 31, 2024, was $9.3 million.
• Annovis Bio plans to submit a plan to the NYSE within 45 days, outlining actions to regain compliance within 18 months.
• The NYSE will review the plan and determine if Annovis Bio has demonstrated a reasonable ability to comply within the given timeframe.
• If the plan is not submitted or accepted, the NYSE may initiate delisting proceedings.
• If the plan is accepted, Annovis Bio's stock will continue to be listed with a '.BC' designation, which will be removed upon regaining compliance.
• The notice does not immediately impact the listing of Annovis Bio's common stock, its business operations, or its reporting obligations with the SEC.
• William Fricker will no longer serve as interim Chief Financial Officer, effective March 27, 2025, by mutual agreement; Maria Maccecchini will continue as principal financial officer on an interim basis.

Sentiment

Score: 3

Explanation: The announcement is negative due to the notification of non-compliance with NYSE listing standards, indicating financial challenges for the company. While the company is taking steps to address the issue, the risk of delisting and the '.BC' designation on the stock are concerning.

Positives

• The notice does not immediately impact the listing of the company's common stock.
• The company has a period of 18 months to regain compliance with NYSE listing standards.
• The notice does not affect the company's business operations or reporting obligations with the SEC.
• The departure of the interim CFO was by mutual agreement and not due to any disagreement or dispute with the company.

Negatives

• The company's market capitalization and stockholders' equity are below the NYSE's continued listing standards.
• There is a risk of delisting if the company fails to submit an acceptable plan or comply with it within 18 months.
• The company's stock will have a '.BC' designation, indicating non-compliance with listing standards.

Risks

• Failure to develop and execute a plan acceptable to the NYSE to regain compliance.
• Potential suspension of trading of the company's common stock on the NYSE.
• Inability to meet continued listing standards at the end of the 18-month cure period.
• Uncertainties related to capital market conditions and the company's ability to manage its business.

Future Outlook

The company intends to submit a plan to the NYSE within 45 days to regain compliance with listing standards within 18 months, but there is no guarantee that the plan will be accepted or that the company will be able to execute it successfully.

Industry Context

Many small-cap biotech companies face challenges in maintaining listing compliance, especially those in the clinical stage with limited revenue. Market volatility and clinical trial outcomes can significantly impact market capitalization.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum $50 million market capitalization required for continued listing on major exchanges like the NYSE and Nasdaq.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX), which are also focused on neurodegenerative diseases, have experienced significant market cap fluctuations based on clinical trial results and regulatory developments.
• A market capitalization below $50 million can limit access to institutional investors and increase stock price volatility, making it more difficult to raise capital and fund ongoing research and development.

Management Changes

Stakeholder Impact

• Shareholders may experience increased stock price volatility and potential dilution if the company needs to raise capital.
• Employees may face uncertainty due to the company's financial challenges and potential restructuring.
• The company's ability to fund research and development may be impacted, potentially affecting the development of new therapies for neurodegenerative diseases.

Next Steps

• Annovis Bio will submit a plan to the NYSE within 45 days to regain compliance.
• The NYSE will review the plan within 45 days of submission.
• The NYSE will review the company on a quarterly basis to confirm compliance with the plan.

Key Dates

Keywords

NYSE, listing standards, market capitalization, stockholders equity, compliance, delisting, Annovis Bio, ANVS